Page 31 - ARNM-3-3
P. 31
Advances in Radiotherapy
& Nuclear Medicine Brachytherapy versus external beam in local dose escalation
Acute skin toxicity was less were similar between groups Age≤65 years (p<0.010), cT1 – 2 stage (p=0.004), and bIRT improved OS. of mortality. DMFS was better in the bIRT group (p=0.015) with a low rate of stoma formation for LC (p=0.042); reduced CRLR (p=0.004) and increased OS (p=0.012). significantly associated with OS. N stage was the only significant Higher LC was associated with: (i) lymph node involvement (p=0.03), (ii)
Main results common in the IRT boost group, but long-term morbidity and QoL (p=0.015) were associated with Tumor stage cT3 – 4 (p=0.004) and age>65 years (p=0.001) were associated with an increased risk EBRT-CHT+bIRT was associated In N1, bIRT was a prognostic factor OTT ≤78 days was associated with N stage and OTT (≤78 days) were prognostic factor for CFS (p=0.0001)
Median FU bEBRT: 45±33; bIRT: 60±34 71 (range: 2 – 158) 86 (range: 36 – 168) 71.5 (range: 1.2 – 121) 83 (range: 18 – 169)
Late toxicity bIRT: 19%; bEBRT: 30% Chronic proctitis: 3.8% (overall)
Acute toxicity bEBRT: 43%; bIRT: 15%; p=0.008 bIRT: 19%; bEBRT: 30% - - - - - - -
bEBRT: 5 y: 66%; 10 y: 52% bIRT: 5 y: 66%; 10 y: 44% bEBRT: bIRT: p=0.015 bEBRT: 5 y: 68% bIRT: 5 y: 75% bEBRT: bIRT: -
OS 2 y: 76.2%; 5 y: 51.6% 2 y: 91.2%; 5 y: 78.7%; 5 y: 73.3% 5 y: 75.5%
CSS bIRT 5 y CSS: 100% - bEBRT: 5y: 78% bIRT: 5y: 91% - - CSS: Cancer-specific survival; DMFS: Distant metastasis-free survival; EBRT: External beam radiotherapy; FU: Follow-up; Gy: gray; HDR: High-dose rate; IRT: Interventional radiotherapy; LC: Local control; LDR: Low-dose rate; n: Number; N.A: Not available; OS: Overall survival; OTT: Overall treatment time; PDR: Pulsed-dose rate; pts: Patients; QoL: Quality of life; R
DMFS bEBRT: 5 y : 77% bIRT: 5 y: 95% p=0.015 bEBRT: 5 y: 85% biRT: 5 y: 78% Abbreviations: bEBRT: Boost external beam radiotherapy; bIRT: Boost interventional radiotherapy; CFS: Colostomy-free survival; CHT: Chemotherapy; CRLR: Complete local response;
- - -
bEBRT: 84.6%; p=0.5 bIRT: (N0): bEBRT: 5 y: 68% bIRT: bEBRT: 87.5%; bEBRT: 68%; bIRT: 89%; p=0.02 62%; 5 y bIRT: 79%; p=0.021
LC bIRT: 89.7%; Early stage 5 y LC 100% 2 y: 75.6%; 2 y: 86.1%; 5 y: 83.9% bIRT: 97.2% 5 y bEBRT:
Boost treatment n pts 3D EBRT±CHT+bEBRT (47 pts) vs. HDR bIRT (34 pts) 3D 123 EBRT+CHT+bEBRT (21 pts) vs. PDR bIRT (102 pts) EBRT±CHT +(Electron) bEBRT (16 pts) vs. LDR bIRT (36 pts) EBRT±CHT +(Photon/electron) bEBRT (49 pts) vs. LDR bIRT (50 pts) EBRT±CHT+bEBRT 134 (18 pts) vs. LDR bIRT (116 pts)
Table 6. Summary of anal cancer studies Study Period 81 Retr 1998 – 2003 Retr 2003 – 2014 52 Retr 2000 – 2011 99 Retr 2000 – Moureau-Zabotto 2005 Retr 1976 – 1993
Oehler-Janne
Allal et al. 34
Authors
et al. 30
Volume 3 Issue 3 (2025) Arcelli et al. 31 Kent et al. 32 23 et al. 33 doi: 10.36922/ARNM025160017
